We are live on ! Find out more
ATRS

Antares Pharma, Inc.
ATRS

Delisted

ATRS was delisted on the 23rd of May, 2022.

Back to rankings

87 hedge funds and large institutions have $107M invested in Antares Pharma, Inc. in 2014 Q4 according to their latest regulatory filings, with 16 funds opening new positions, 20 increasing their positions, 33 reducing their positions, and 9 closing their positions.

New
Increased
Maintained
Reduced
Closed

78% more first-time investments, than exits

New positions opened: 16 | Existing positions closed: 9

40% more capital invested

Capital invested by funds: $76.7M → $107M (+$30.7M)

6% more funds holding

Funds holding: 82 → 87 (+5)

39% less repeat investments, than reductions

Existing positions increased: 20 | Existing positions reduced: 33

97% less call options, than puts

Call options by funds: $9K | Put options by funds: $291K

Holders
87
Holders Change
+5
Holders Change %
+6.1%
% of All Funds
2.32%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
16
Increased
20
Reduced
33
Closed
9
Calls
$9K
Puts
$291K
Net Calls
-$282K
Net Calls Change
+$58K

Top Buyers

Rank Fund Capital Flow
1
BC
Broadfin Capital
New York
+$2.25M
2
BFA
BlackRock Fund Advisors
California
+$965K
3
DM
Deerfield Management
New York
+$631K
4
B
Baird
Wisconsin
+$566K
5
Vanguard Group
Vanguard Group
Pennsylvania
+$399K

Top Sellers

Rank Fund Capital Flow
1
Millennium Management
Millennium Management
New York
-$6.74M
2
GTC
Ghost Tree Capital
New York
-$2.01M
3
Citadel Advisors
Citadel Advisors
Florida
-$555K
4
WHI
William Harris Investors
Illinois
-$444K
5
BIT
BlackRock Institutional Trust
California
-$224K
Name Holding Trade Value Shares
Change 		Change in
Stake
TA
26
Teachers Advisors
New York
$425K – – –
MC
27
Menta Capital
California
$398K +$348K +154,780 New
Wells Fargo
28
Wells Fargo
California
$396K +$40.5K +18,043 +13%
Swiss National Bank
29
Swiss National Bank
Switzerland
$372K +$16.8K +7,500 +5%
Susquehanna International Group
30
Susquehanna International Group
Pennsylvania
$336K -$123K -54,574 -29%
TC
31
TFS Capital
Pennsylvania
$317K -$89.8K -39,989 -24%
Citigroup
32
Citigroup
New York
$314K +$17.4K +7,748 +7%
NPC
33
National Planning Corporation
California
$303K -$1.12K -500 -0.4%
Commonwealth Equity Services
34
Commonwealth Equity Services
Massachusetts
$277K +$39.9K +17,750 +20%
D.E. Shaw & Co
35
D.E. Shaw & Co
New York
$272K +$238K +105,998 New
MLICM
36
Metropolitan Life Insurance Company (MetLife)
New York
$258K – – –
Goldman Sachs
37
Goldman Sachs
New York
$256K +$9.05K +4,028 +4%
RhumbLine Advisers
38
RhumbLine Advisers
Massachusetts
$247K +$6.35K +2,825 +3%
CS
39
Credit Suisse
Switzerland
$242K +$91.6K +40,788 +76%
VOYA Investment Management
40
VOYA Investment Management
Georgia
$241K – – –
NFA
41
Nationwide Fund Advisors
Ohio
$230K -$2.26K -1,007 -1%
Renaissance Technologies
42
Renaissance Technologies
New York
$221K -$134K -59,758 -41%
Deutsche Bank
43
Deutsche Bank
Germany
$219K -$47K -20,905 -20%
OC
44
Oppenheimer & Co
New York
$204K -$85.5K -38,073 -32%
Morgan Stanley
45
Morgan Stanley
New York
$192K +$146K +65,023 +644%
State Board of Administration of Florida Retirement System
46
State Board of Administration of Florida Retirement System
Florida
$189K – – –
AIG
47
American International Group
New York
$189K -$6.53K -2,905 -4%
BA
48
BlackRock Advisors
Delaware
$173K -$9.26K -4,120 -6%
UBS AM
49
UBS AM
Illinois
$144K – – –
DCM
50
Driehaus Capital Management
Illinois
$128K +$112K +50,000 New
1
2
3 4

ATRS Hedge Fund Activity: Q4 2014 in Review

87 of the 3,749 institutional investors tracked by Wall St. Rank reported a position in Antares Pharma, Inc. (ATRS) for Q4 2014, worth a combined $107M — up 40% from $76.7M a quarter earlier.

Buyers outnumbered sellers: 16 funds opened new ATRS positions and 9 closed out — a net gain of 7 holders — while 20 added to existing stakes and 33 trimmed.

The largest buyer was Broadfin Capital, adding an estimated $2.25M. The largest seller was Millennium Management, cutting an estimated $6.74M.

  • 87 institutional investors held Antares Pharma, Inc. (ATRS) as of Q4 2014, up from 82 in Q3 2014.
  • Funds reported $107M of Antares Pharma, Inc. stock for Q4 2014, up 40% quarter-over-quarter.
  • 16 funds opened new Antares Pharma, Inc. positions in Q4 2014 and 9 closed out, a net change of +7 holders.
  • The largest Antares Pharma, Inc. buyer in Q4 2014 was Broadfin Capital, an estimated $2.25M added.
  • The largest Antares Pharma, Inc. seller in Q4 2014 was Millennium Management, an estimated $6.74M sold.

Based on aggregated 13F filings for Q4 2014.